An Introduction to Heart Failure
Much progress has been made in the management of heart failure in patients with reduced ejection fraction (HFrEF) and the development of therapies for HF with preserved ejection fraction is ongoing. Promising new therapeutics in HF include a dual-acting angiotensin receptor-neprilysin inhibitor, soluble guanylate cyclase (sGC) stimulator and a cardiac myosin activator. It is hoped that gene therapy will be available for patients with HFrEF in the near future.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer- reviewed articles from our journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Heart Failure Content
Natriuretic Peptide-guided Therapy for Heart Failure
Heart International. 2022;16(2):112–6 DOI: https://doi.org/10.17925/HI.2022.16.2.112
Heart failure (HF) is a complex syndrome caused by a variety of cardiac and non-cardiac diseases, and is associated with high mortality and hospitalization rates.1 Treatment has been traditionally based on a detailed history and physical examination. However, since cardiac biomarkers reflect the pathophysiology of HF, they add information to the clinical findings.1 The most widely used […]
Addressing cardiorenal outcomes in CKD and T2D: What are the key considerations for daily practice?
Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D
- Identify the epidemiological and pathophysiological drivers behind the progression of CKD
- Recognize the specific renal and cardiovascular risks associated with CKD and T2D and the therapies available to address them
- Apply the latest clinical guidelines to treating patients with CKD and T2D in daily practice
Divaka Perera, ESC 2022: Percutaneous revascularisation in patients with severe ischaemic cardiomyopathy, the REVIVED trial
The REVIVED study aimed to assess whether the addition of stents when treating patients with severe ischaemic cardiomyopathy would be beneficial to patient outcomes. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the REVIVED trial, its outcomes and how they will affect the current treatment paradigm. […]
Divaka Perera, ESC 2022: The unmet needs in patients with heart failure due to ischaemic cardiomyopathy
In an ideal scenario, patients with ischaemic cardiomyopathy would receive specific treatment options beyond the general heart failure management currently in place. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the unmet needs in this population and give an evaluation of surgical and percutaneous revascularization in […]
Caroline Sindet-Pedersen, ESC 2022: SARS-CoV-2 mRNA vaccines in patients with heart failure
Studies investigating the safety and efficacy of the severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2) mRNA vaccines lacked representation of patients with heart failure. In this touchCARDIO interview, we speak with Dr Caroline Sindet-Pedersen (Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark) to discuss the study presented at ESC 2022 that aimed to investigate […]
Mandeep Mehra, ESC 2022: HeartMate 3™ left ventricular assist device for heart failure, the MOMENTUM 3 study 2- and 5-year results
Following its positive 2-year results, the MOMENTUM 3 study in patients with heart failure was extended to assess 5-year outcomes of the HeartMate 3™ left ventricular assist device. In this touchCARDIO interview, we speak with Dr Mandeep Mehra (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) to discuss the MOMENTUM 3 study and […]
Mandeep Mehra, ESC 2022: Advances in left ventricular assist devices (LVADs) for heart failure and the advantages of the HeartMate 3™ LVAD
Left ventricular assist devices (LVADs) are utilised to treat patients with heart failure, the HeartMate 3™ being an example. In this touchCARDIO interview, we speak with Dr Mandeep Mehra (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) to discuss the advances in LVADs and the advantages the HeartMate 3™ (HM3) LVAD holds over […]
Camilla Fuchs Andersen, ESC 2022: Empagliflozin for HFrEF, the Empire HF trial
The Empire-HF study aimed to investigate the effect of the empagliflozin on erythropoiesis in patients with heart failure with reduced ejection fraction (HFrEF). In this touchCARDIO interview, we speak with Dr Camilla Fuchs Andersen (Herlev Hospital, Herlev, Denmark) to discuss the Empire HF trial and provide an insight into potential mechanisms of empagliflozin on erythropoiesis […]
Jawad Haider Butt, ESC 2022: A post hoc analysis of PARAGON-HF assessing sacubitril/valsartan in patients with HFpEF according to frailty status
The post hoc analysis of PARAGON-HF assessed the efficacy of sacubitril/valsartan, compared with valsartan, according to frailty status in patients with heart failure (HF) with preserved fraction (HFpEF). Frailty is a common issue, with patients less likely to receive pharmacological therapy due to a less favourable benefit/risk profile. In this touchCARDIO interview, we speak with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!